Femasys, Inc. (Nasdaq: FEMY), a leading biomedical company focused on women’s health, has announced that the first infertility clinics in California and Florida have begun offering its innovative fertility treatment, FemaSeed. The Reproductive Fertility Center in Los Angeles, California, and Palm Beach Fertility Center in Boca Raton, Florida, are the first to provide this cost-effective treatment to patients.
Kathy Lee-Sepsick, CEO of Femasys, expressed enthusiasm about the expansion, stating, “We are excited to welcome these fertility centers as our first customers and anticipate broader acceptance as FemaSeed’s distinct benefits become more widely recognized.”
FemaSeed is a novel form of artificial insemination that delivers sperm directly into the fallopian tube, targeting the ovulation side to promote natural fertilization. It offers a more affordable and less invasive alternative to procedures like in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Dr. Peyman Saadat from Reproductive Fertility Center highlighted FemaSeed’s affordability, saying, “We are eager to offer our patients a new fertility treatment option that is both effective and financially accessible.”
Dr. David Kreiner from Palm Beach Fertility Center praised FemaSeed’s success rates, noting the improved outcomes compared to traditional intrauterine insemination (IUI). “We are thrilled to be among the first to provide this groundbreaking treatment,” Kreiner said.
With its promising clinical results and affordability, FemaSeed is poised to become a key option for those seeking fertility solutions.
Related topics:
